Collectively, our findings provide strong evidence that MARCO downregulating antibody significantly enhances the anti-tumor immune response of anti-PD-1 immunotherapy by suppressing MDSC differentiation, altering TAM properties, and promoting the infiltration of CD8+ T cells and NK cells. This evidence concerns the gene PDCD1 and neoplasm.